Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00938158 · ClinicalTrials.gov registry record · Phase 1
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00938158 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 75 participants.
The verdict
NCT00938158, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function, including subjects requiring hemodialysis.
Interventions
- BIOLOGICAL albiglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2009-08-05 |
| Est. Completion | 2011-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00938158
The ClinicalTrials.gov registry entry for NCT00938158 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which albiglutide is the first listed.
NCT00938158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00938158 about?
NCT00938158 is a clinical study titled "A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.". The purpose of this study is to assess the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function, including subjects requiring hemodialysis.
What is the current status of trial NCT00938158?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2009-08-05. Estimated completion is 2011-04-12.
What interventions are being tested in trial NCT00938158?
The interventions under investigation include: albiglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00938158?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.